Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 4, 2002, Pages 495-502

  Boswell, F J ^a   Andrews, J M ^a   Jevons, G ^a   Wise, R ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; TIME;

EID: 0036800213     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf152     Document Type: Article

References (26)

1. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P. & Wise, R. (1997). In vitro activity of Bay 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
2. Child, J., Andrews, J., Boswell, F., Brenwald, N. & Wise, R. (1995). The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy 35, 869-76.
3. Wise, R., Brenwald, N. P., Andrews, J. M. & Boswell, F. (1997). The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. Journal of Antimicrobial Chemotherapy 39, 447-52.
4. Wise, R. & Andrews, J. M. (1999). The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. Journal of Antimicrobial Chemotherapy 44, 679-88.
5. Gill, M. J., Brenwald, N. P. & Wise, R. (1999). Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 43, 187-9.
6. Pan, X.-S., Ambler, J., Mehtar, S. & Fisher, L. M. (1996). Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 40, 2321-6.
7. Soman, A., Honeybourne, D., Andrews, J., Jevons, G. & Wise, R. (1999). Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy 44, 835-8.
8. Andrews, J. M., Honeybourne, D., Jevons, G., Brenwald, N. P., Cunningham, B. & Wise, R. (1997). Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy 40, 573-7.
9. Brenwald, N. P., Gill, M. J. & Wise, R. (1999). Grepafloxacin vs. pneumococci resistant to fluoroquinolones by a putative efflux mechanism. Drugs 58, Suppl. 2, 117-8.
10. Brenwald, N. P., Gill, M. J. & Wise, R. (1998). Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 42, 2032-5.
11. British Society for Antimicrobial Chemotherapy Working Party Report. (2001). Antimicrobial susceptibility testing. Journal of Antimicrobial Chemotherapy 48, Suppl, S1, 5-28.
12. Miles, A. A., Misra, S. S. & Irwin, J. O. (1938). The estimation of the bactericidal power of the blood. Journal of Hygiene 38, 732-49.
13. National Committee for Clinical Laboratory Standards. (1992). Methods for Determining Bactericidal Activity of Antimicrobial Agents: Tentative Guideline M26-T. NCCLS, Villanova, PA, USA.
14. Gill, M. J. & Wise, R. (1998). Activity of grepafloxacin against pneumococci resistant to fluoroquinolones by a putative efflux mechanism. In Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998. Abstract C-52, p. 83. American Society for Microbiology, Washington, DC, USA.
15. Beyer, R., Pestova, E., Millichap, J. J., Stosor, V., Noskin, G. A. & Peterson, L. R. (2000). A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: Evidence for diminished moxifloxacin, sparfloxacin and trovafloxacin efflux. Antimicrobial Agents and Chemotherapy 44, 798-801.
16. Alovero, F. L., Pan, X.-S., Morris, J. E., Manzo, R. H. & Fisher, L. M. (2000). Engineering the specificity of antibacterial fluoroquinolones: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrobial Agents and Chemotherapy 44, 320-5.
17. Pestova, E., Millichap, J. J., Noskin, G. A. & Peterson, L. R. (2000). Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. Journal of Antimicrobial Chemotherapy 45, 583-90.
18. Boswell, F. J., Andrews, J. M. & Wise, R. (1997). Pharmacodynamic properties of BAY 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimicrobial Agents and Chemotherapy 41, 1377-9.
19. Wright, D. H., Brown, G. H., Peterson, M. L. & Rotschafer, J. C. (2000). Application of fluoroquinolone pharmacodynamics. Journal of Antimicrobial Chemotherapy 46, 669-83.
20. Morrissey, I. & George, J. T. (2000). Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. Journal of Antimicrobial Chemotherapy 45, Suppl. S1, 101-6.
21. Eliopoulos, G. M. & Eliopoulos, C. T. (1993). Activity in vitro of the quinolones. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds), pp. 161-93. American Society for Microbiology, Washington, DC, USA.
22. Fung-Tomc, J., Kolek, B. & Bonner, D. P. (1993). Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 37, 1289-96.
23. Petersen, L. R. (1993). Quinolone resistance in clinical practice: occurrence and importance. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds), pp. 119-37. American Society for Microbiology, Washington, DC, USA.
24. Thomson, K. S. (2000). Minimizing quinolone resistance; are the new agents more or less likely to cause resistance? Journal of Antimicrobial Chemotherapy 45, 719-23.
25. Firsov, A. A., Lubenko, I. Y., Vostrov, S. N., Kononenko, O. V., Zinner, S. H. & Portnoy, Y. A. (2000). Comparative pharmaco-dynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. Journal of Antimicrobial Chemotherapy 46, 725-32.
26. Lubenko, I., Vostrov, S., Portnoy, Y., Zinner, S. & Firsov, A. (2001). Preventing the production of resistant mutants of Staphylococcus aureus with moxifloxacin and levofloxacin: dose ranging studies using an in vitro dynamic model. Clinical Microbiology and Infection 7, Suppl. 1, 166.